Phase i clinical trial of (NPAz2)2NSOAz: ‘SOAz’
- 1 June 1983
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 10 (3), 178-181
- https://doi.org/10.1007/bf00255757
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Acute toxicity study of 1,3,3,5,5‐pentaziridino‐1‐thia‐2,4,6‐triaza‐3,5‐diphosphorine‐1‐oxide (a new antitumor agent with an inorganic ring) in mice, rats and dogsJournal of Applied Toxicology, 1984
- Clinical pharmacokinetics of (NPAz2)2NSOAz: ‘SOAz’Cancer Chemotherapy and Pharmacology, 1983
- Effect of 1,3,3,5,5-pentaziridino-1-thia-2,4,6-triaza-3,5-diphosphorine-1-oxide, a new antitumor agent with inorganic ring, on various experimental tumors.Journal of Pharmacobio-Dynamics, 1982
- New designs in inorganic ring systems as anticancer drugs. Antitumor activity of the aziridino (ethyleneimino) derivatives (NPAz2)2NSOX with X = F, Az, PhCancer Letters, 1981
- Antitumour activity of some cyclophosphazenesEuropean Journal of Cancer (1965), 1979